CA
NZ
UK
AU
IND
US
Mark Reinstra, Chief Legal Officer and Corporate Secretary of Roblox Corp, filed a Form 4 on August 20, 2026, disclosing the sale of 6,250 shares of Class A Common Stock on August 19, 2026.
A Form 4 filed on August 20, 2026 with the U.S. Securities and Exchange Commission discloses that Christophe Beck, Chairman, President and CEO of Ecolab Inc. (NYSE:ECL), sold 17,862 shares of common stock on August 18, 2026 at a weighted average price of $280.138 …
Christopher A. Scott, Executive Vice President and Chief Commercial Officer of Matson, Inc. (NYSE:MATX), filed a Form 4 on August 20, 2026, disclosing the sale of 600 shares of common stock on August 19, 2026.
Peter T. Heilmann, Executive Vice President, Chief Administrative Officer and General Counsel of Matson, Inc. (NYSE:MATX), filed a Form 4 on August 20, 2026, disclosing the sale of 5,000 shares of common stock on August 19, 2026.
William D. McCombe, Chief Financial Officer of Cytek Biosciences, Inc. (NASDAQ:CTKB), filed a Form 4 on August 20, 2026, reporting the vesting of three separate restricted stock unit awards and the withholding of shares to cover tax obligations, all transacted on August 18, 2026.
A Form 4 filed on August 20, 2026 reports that Glenn P. Muir, a director of Cytek Biosciences, Inc. (NASDAQ:CTKB), acquired 3,086 shares of common stock on August 18, 2026 through the vesting of restricted stock units.
Wenbin Jiang, President and CEO of Cytek Biosciences, Inc. (NASDAQ:CTKB), filed a Form 4 on August 20, 2026, disclosing the vesting of restricted stock units and related tax-withholding share disposals on August 18, 2026.
A Statement of Changes in Beneficial Ownership was filed on August 20, 2026, disclosing a purchase of BorgWarner Inc. common stock by director Rajesh Kalathur on August 19, 2026.
Pablo J. Cagnoni, President and Global Head of R&D at Incyte Corp, filed a Form 4 on August 20, 2026, disclosing the sale of 10,801 shares of common stock on August 19, 2026, pursuant to a Rule 10b5-1 trading plan.
Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corporation (NASDAQ:UTHR), filed a statement of changes in beneficial ownership on August 20, 2026, reporting the exercise of stock options and the sale of resulting common stock shares on August 19, 2026, pursuant to a …
Please wait processing your request...